Skip to main content
. 2015 Apr 1;13(3):155–166. doi: 10.1089/adt.2015.639

Fig. 3.

Fig. 3.

Pilot screening to validate the BlaM assay for HTS. The BlaM virus–cell fusion assay in a 384-well format was validated for HTS, using the library of pharmacologically active compounds (LOPAC). (A) The fusion signal and the inhibitory effect of C52L on the fusion signal across four screening plates. The data shown are average with SD from 16 replicates. (B) S/B ratio (upper panel) and Z′ for four testing plates. (C) Scatter plot of pilot screening of 1,280 compounds using % Fusion (X-axis) against the % of Control (viability, Y-axis). The potential positives (rectangular region) are compounds with % Fusion <30 and % of Control (viability) >80.